ESR1 and cancer: Since the simultaneous reduction in cellular concentration of the above mentioned and other cancer-relevant Hsp90 clients (e.g. estrogen receptor α, Akt, etc.)could have potent synergistic effects in cancer therapy [15,16], it is not surprising that 22 N-terminal pan-Hsp90 inhibitors have been clinically investigated [17–19].